Clinical trials: Advanced Solid, Malignant Tumors
Advanced Solid Tumors
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
This is an open-label, multicenter Phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0501 in participants with advanced solid tumors.
- Trial name
- NCT06331559
- Testing
- SIM0501 Tablets, SIM0501 in combination with olaparib
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Malignant Solid Tumor
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to…
- Trial name
- NCT07682870
- Testing
- Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Virogin Biotech Ltd.
Advanced Solid Tumors
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
- Trial name
- NCT05541822
- Testing
- Vabametkib, Lazertinib
- Where
- 24 sites in United States, South Korea and 1 more
- Volunteers
- 178 people
- Sponsor
- Abion Inc
Solid Tumors, Lymphoma
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.
- Trial name
- NCT01844583
- Testing
- Alisertib, Esomeprazole, Rifampin
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Neoplasms, Pancreatic
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis.
- Trial name
- NCT03681951
- Testing
- GSK3145095, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with…
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
- Trial name
- NCT06162221
- Testing
- RMC-6291, RMC-6236, Pembrolizumab
- Where
- 98 sites in United States, Australia and 11 more
- Volunteers
- 616 people
- Sponsor
- Revolution Medicines, Inc.
Advanced Solid Tumors
Study of Tesetaxel in Japanese Patients With Solid Tumors
Tesetaxel is an orally active tubulin-binding inhibitor of the taxane class. Evaluation of tesetaxel in Japanese patients has been limited.
- Trial name
- NCT01337310
- Testing
- Tesetaxel
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Genta Incorporated
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Solid Tumors, Lymphoma
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary…
- Trial name
- NCT02503423
- Testing
- ASTX660
- Where
- 68 sites in United States, Belgium and 6 more
- Volunteers
- 253 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumors
A Study of Q-1802 in Patients With Advanced Solid Tumors
Q-1802 is a bispecific antibody targeting both the tumor-specific antigen Claudin 18.2 and the immune checkpoint PD-L1. This is a multi-center, single-arm, open-label design to evaluate the safety and tolerance of Q-1802 in…
- Trial name
- NCT04856150
- Testing
- Q-1802
- Where
- 4 sites in China
- Volunteers
- 66 people
- Sponsor
- QureBio Ltd.
Advanced Solid Tumors
A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors
The purpose of this study is to estimate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Sirolimus for Injection (Albumin Bound) in patients with solid malignancies.
- Trial name
- NCT05125523
- Testing
- Sirolimus for Injection (Albumin Bound)
- Where
- China
- Volunteers
- 264 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Positron-Emission Tomography, Metastatic Solid Tumors
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by immunohistochemical staining in patients with…
- Trial name
- iCorrelate (NCT03802123)
- Testing
- ⁸⁹Zr-Df-IAB22M2C
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- ImaginAb, Inc.
Advanced Solid Tumor
A Study of KM602 in Patients With Advanced Solid Tumors
This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and activity of KM602 as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT05766527
- Testing
- KM602
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Advanced Solid Tumors Harboring RAS Mutations or Amplifications
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.
- Trial name
- NCT07142980
- Testing
- HRS-7172 Tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neoplasms
A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.
The purpose of this study is to assess the safety of JNJ-26854165 (a new drug in development for cancer) in patients with advanced or refractory solid tumors on the maximum dose tolerated by these patients.
- Trial name
- NCT00676910
- Testing
- JNJ-26854165
- Volunteers
- 71 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Advance Solid Tumors, Advanced Malignant Solid Tumors
A Study of CS231295 in Patients With Advanced Solid Tumors
This is a Phase I, single-arm, open-label, dose-escalation, multicenter clinical study of CS231295 in patients with advanced solid malignant tumors.
- Trial name
- NCT07612488
- Testing
- a small molecular multi-target kinase inhibitor
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- ThalassaX Therapeutics United States Ltd
Advanced Solid Tumor
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors
- Trial name
- NCT05036291
- Testing
- NB004 tablets
- Where
- 4 sites in United States, China
- Volunteers
- 25 people
- Sponsor
- Ningbo Newbay Technology Development Co., Ltd
Advanced Solid Tumors Amenable to Anthracycline Therapy, Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy
L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Prospective, open-label, non randomized, dose escalation study that will be conducted in sequential cohorts of patients.
- Trial name
- NCT02076620
- Testing
- L19TNFα, Doxorubicin
- Where
- 2 sites in Germany, Italy
- Volunteers
- 29 people
- Sponsor
- Philogen S.p.A.
Advanced Solid Tumors
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select…
- Trial name
- NCT02261220
- Testing
- MEDI4736, tremelimumab
- Where
- 75 sites in United States, Canada and 7 more
- Volunteers
- 380 people
- Sponsor
- MedImmune LLC
Advanced Solid Tumors
A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
The purpose of this study is to obtain QTc data, to assess the effects of tivozanib on ECG morphology, and to determine the pharmacokinetic pharmacodynamic (PK-PD) relationship between any observed changes in cardiac…
- Trial name
- NCT01210846
- Testing
- tivozanib
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.